[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"bloating\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:bloating":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,10,0,[8,41,70,100,122,150,182,205,237,262],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100561945","diaphragmatic-breathing-for-the-treatment-of-bloating-and-distension-100561945",false,"NCT06596759","Diaphragmatic Breathing for the Treatment of Bloating and Distension","Diaphragmatic Breathing for the Treatment of Bloating and Distension: a Prospective Pilot Study","Inclusion Criteria:\n\n* Referred for breath testing for the indication of bloating.\n\nExclusion Criteria:\n\n* Not referred for breath testing for the indication of bloating.",true,"ALL","18 Years",{"count":20,"type":21},35,"ESTIMATED","INTERVENTIONAL",[24],"NA","The purpose of this study is to evaluate the efficacy of diaphragmatic breathing using the validated Mayo Bloating Questionnaire.",[27],"Bloating","RECRUITING","2026-06-02",{"date":31,"type":32},"2026-06-04","ACTUAL",{"date":34,"type":32},"2024-10-21",{"date":36,"type":21},"2026-12-30",{"name":38,"class":39},"Mayo Clinic","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":47,"targetDuration":4,"studyType":22,"phases":49,"briefSummary":50,"conditions":51,"keywords":55,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":40},"100640341","a-study-evaluating-the-impact-of-regular-fodmap-targeting-digestive-enzyme-blend-use-on-gastrointestinal-symptoms-in-individuals-with-self-reported-bloating-100640341","NCT07591584","A Study Evaluating the Impact of Regular FODMAP-targeting Digestive Enzyme Blend Use on Gastrointestinal Symptoms in Individuals With Self-Reported Bloating","Inclusion Criteria:\n\n* Individuals aged 18 years old or older\n* Screening score of \\>= 55 on the PROMIS Scale v1.1 - Gastrointestinal Gas and Bloating 13a scale.\n* Screening severity score of \\>= 55 on the PROMIS Scale v1.0 - Gastrointestinal Belly Pain scale.\n* Screening score of \\\u003C10 on the Generalized Anxiety Disorder 7-item (GAD-7) scale\n* Adults with or without IBS are eligible; participants with IBS experiencing symptoms must meet the Rome IV criteria as determined by the Rome IV Diagnostic Questionnaire (R4DQ) IBS Module.\n* Able to maintain 80% compliance with daily questionnaires during the 2 week run-in period.\n* In good general health at the time of screening (Investigator discretion).\n* Able to read and understand English and provide informed consent.\n* Able to use a personal smartphone device and download Chloe by People Science.\n* Able to receive shipment of the product at an address within the United States.\n* Able to complete study assessments over the course of up to 19 weeks.\n\nExclusion Criteria:\n\n* Do not have a personal smartphone, internet access, or unwilling to download Chloe.\n* Concomitant Therapies:\n\nParticipants receiving any of the following treatments or therapies are excluded:\n\n* Any investigational therapies or treatments (pharmaceuticals, devices, supplements) within 30 days prior to randomization.\n* Ongoing psychological therapies specifically targeting gastrointestinal symptoms or functional disorders, including but not limited to GI-directed Cognitive Behavioral Therapy (CBT), GI hypnotherapy, or other therapies for Disorders of Gut-Brain Interaction (DGBI).\n* Treatment with Glucagon-like peptide-1 (GLP-1) agonists (e.g., semaglutide, tirzepatide) within the last 90 days prior to randomization, due to their known effects on gut motility and GI symptoms.\n* Current or recent (within the last 6 months) chemotherapy or immunotherapy for cancer treatment.\n* Current or planned use of any other digestive enzymes prescription or over-the-counter (OTC).\n* Chronic use (defined as daily use for \\>30 days within the last 90 days) of any medication known to have substantial gastrointestinal side effects (e.g., diarrhea, constipation, nausea) that, in the opinion of the Principal Investigator, may confound the assessment of study outcomes. This may include high-dose NSAIDs, opioids, prokinetics, bile acid binders, or certain antibiotics.\n* Variable use of probiotics, fiber supplements, laxatives, stool softeners, antidiarrheals (if taking) in the last 30 days. Variable use is defined as use of any probiotic, fiber supplement, laxative, stool softener, or antidiarrheal with a dose change greater than 50% in the last 30 days or initiation or discontinuation of a gut-active product in the last 30 days.\n\n  * Other Illnesses or Conditions:\n\nParticipants who have the following comorbidities or gastrointestinal illnesses are excluded:\n\n* Currently diagnosed with Alcohol Use Disorder and\u002For Substance Use Disorder\n* Currently pregnant, planning to become pregnant in the next 4 months, or breastfeeding\n* History of bariatric or other significant gastrointestinal surgery (e.g., small bowel resection, total colectomy) that has permanently altered GI anatomy or function. Standard appendectomy or cholecystectomy are generally permitted.\n\nAny underlying medical conditions or comorbidities that may confound the assessment of digestive symptoms or the evaluation of the study outcomes (e.g., Type I diabetes, Endometriosis, etc.).\n\n* Acute gastroenteritis within the past 4 weeks;\n* New diagnosis workup planned during study that may change diagnosis\u002F behavior\u002F medications (eg. colonoscopy prep or major bowel cleanse, upcoming GI consult that could affect eligibility).\n* Have a significant illness, disease or condition which, in the opinion of the principal investigator, may impact their ability to participate in the study or impact the study outcomes.\n\n  * Self-reported known hypersensitivity or previous allergic reaction to corn and\u002For any previous reaction to digestive enzyme supplements (eg. Beano and Lactaid)\n  * Comorbid GI conditions: IBD - Ulcerative Colitis or Crohn's Disease, Microscopic Colitis, history of small bowel or colonic surgeries, Celiac disease, or Bile Acid Malabsorption (BAM).\n  * Screening score of ≥10 on the Generalized Anxiety Disorder 7-item (GAD-7) scale\n  * On a low FODMAP diet based on FODMAP FFQ results at Screening\n  * History of following a low FODMAP diet in the past 6 months (self-reported)\n  * Any history of following LFD (Low FODMAP Diet) with no response (i.e. failed LFD in past)\n  * Participants who are on or plan to initiate a major restrictive or elimination diet, or a structured weight-loss diet, during the study period.\n  * No planned changes in diet, lifestyle or medications for IBS during study period.\n  * Use of any antibiotics, antifungals, or antivirals within 2 weeks prior to randomization.\n  * Participants planning extended travel that would interfere with compliance or study procedures.\n  * Are unlikely for any reason to be able to comply with the trial or considered unsuited for participation in the study by the Principal Investigator.",{"count":48,"type":21},150,[24],"This study is a randomized, double-blind, placebo-controlled, within-individual crossover trial designed to assess the impact of regular use of a consumer-grade FODMAP-targeting digestive enzyme blend (FODZYME®) on gastrointestinal symptoms in adults with self-reported bloating.1\n\nThe study's rationale is based on the fact that fermentable carbohydrates (FODMAPs) are often poorly absorbed and can trigger symptoms like bloating and abdominal pain. While a Low FODMAP Diet (LFD) is clinically validated for symptom relief, it is restrictive. The enzyme blend is intended to offer a more flexible, enzyme-based solution by targeting and breaking down FODMAPs, such as fructan, GOS, and lactose, before they ferment in the colon.\n\nThe primary objective is to evaluate the product's impact on bloating symptoms, measured by the mean PROMIS scale Gastrointestinal Gas and Bloating score. Secondary and exploratory objectives include assessing the impact on overall gastrointestinal symptom severity (IBS-SSS), abdominal pain (PROMIS Belly Pain score), food-related quality of life (FR-QoL-29), and anxiety (GAD-7 scores). The study also aims to evaluate these effects across various Irritable Bowel Syndrome (IBS) subgroups (IBS-C, IBS-D, IBS-M). The trial is a consumer-driven, decentralized research study utilizing validated patient-reported outcome measures that can be completed in a home setting.",[52,27,53,54],"IBS (Irritable Bowel Syndrome)","Abdominal Pain","Gut Health",[56,57,58,59],"bloating","gas","abdominal pain","IBS","2026-05-11",{"date":62,"type":32},"2026-05-15",{"date":64,"type":32},"2026-05-04",{"date":66,"type":21},"2026-10-26",{"name":68,"class":69},"Kiwi Health Inc","INDUSTRY",{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":4,"eligibilityCriteria":76,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":77,"enrollmentInfo":78,"targetDuration":4,"studyType":22,"phases":80,"briefSummary":82,"conditions":83,"keywords":88,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":40},"100633097","phase-3-rifaximin-treatment-in-bloating-predominant-functional-bowel-disorders-100633097","NCT07522255","Rifaximin Treatment in Bloating Predominant Functional Bowel Disorders","The Effect of Rifaximin Treatment in Bloating Predominant Functional Bowel Disorders: A Randomized Double-blind Placebo-Controlled Trial With Gut Microbiota and Intestinal Gas Analysis","Inclusion Criteria:\n\n* Adults aged 18 to 80 years.\n* Rome IV diagnosis of irritable bowel syndrome, functional constipation, or functional abdominal bloating\u002Fdistension.\n* Bothersome bloating with baseline severity of at least 3 on a 7-point Likert scale after adequate constipation treatment, defined as stool frequency from at least 3 times\u002Fweek to 3 times\u002Fday and Bristol Stool Form Scale type 3-5.\n* Colonoscopy, CT colonography, or barium enema performed if clinically indicated as part of standard evaluation for bowel symptoms.\n\nExclusion Criteria:\n\n* History of major gastrointestinal surgery, except appendectomy or laparoscopic cholecystectomy.\n* Inflammatory bowel disease or other inflammatory gastrointestinal conditions.\n* Current use of, or inability to discontinue, medications that may affect intestinal microbiota or gas measurements, including antibiotics, proton pump inhibitors, probiotics, lactulose, NSAIDs, or metformin.\n* Current use of, or inability to discontinue, medications that may affect bloating symptoms, including simethicone, simethicone-containing antispasmodics, or antidiarrheal medications.\n* Underlying conditions known to affect intestinal microbiota composition, including cirrhosis, uncontrolled diabetes mellitus, end-stage renal disease, obesity, malignancy, or psychiatric disorders.\n* Opioid-induced constipation.\n* Known allergy to rifaximin.","80 Years",{"count":79,"type":21},78,[81],"PHASE3","This randomized, double-blind, placebo-controlled trial will evaluate whether a 14-day course of rifaximin improves bloating in adult patients with Rome IV functional bowel disorders in whom bloating is the predominant symptom. Eligible participants with irritable bowel syndrome, functional constipation, or functional abdominal bloating\u002Fdistension and bothersome bloating despite adequate bowel movement management will be assigned in a 1:1 ratio to rifaximin 550 mg three times daily or matching placebo for 2 weeks. The primary endpoint is the proportion of participants with bloating response, defined as at least a 1-point reduction from baseline in a 7-point Likert bloating score at the end of treatment.",[27,84,85,86,87],"Rifaximin","Functional Bowel Disorder","Irritable Bowel Syndrome","Constipation",[84,27,89],"Functional bowel disorder","NOT_YET_RECRUITING","2026-04-03",{"date":93,"type":32},"2026-04-13",{"date":95,"type":21},"2026-04",{"date":97,"type":21},"2027-12",{"name":99,"class":39},"Mahidol University",{"id":101,"slug":102,"hasResults":11,"nctId":103,"briefTitle":104,"officialTitle":104,"acronym":4,"eligibilityCriteria":105,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":106,"targetDuration":4,"studyType":22,"phases":108,"briefSummary":109,"conditions":110,"keywords":111,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":40},"100609497","impact-of-the-inno-cleanse-dietary-supplement-on-gut-health-and-associated-variables-in-healthy-men-and-women-100609497","NCT07215351","Impact of the Inno Cleanse Dietary Supplement on Gut Health and Associated Variables in Healthy Men and Women","Inclusion Criteria:\n\n* experience regular (2 or more days per week) bloating or constipation\n* able to fast a minimum of 12 hours prior to testing visit\n\nExclusion Criteria:\n\n* pregnant, planning to become pregnant, or breastfeeding\n* sensitivity or allergic to any components of the study product (cascara sagrada bark powder, cape aloe leaves extract, senna leaf powder, frangula bark powder fennel seed powder, bentonite clay, burdock root powder, licorice root extract, slippery elm bark powder, Capiscum annuum L. Fruit powder, milk thistle seed powder, hydroxypropyl methylcellulose, cellulose, and silicon dioxide).\n* experienced a severe allergic reaction that resulted in emergency care\n* diagnosed with medical disorders linked to digestive\u002Fgut health such as celiac disease, crohn's disease, gastroesophageal reflux disease, heartburn, irritable bowel syndrome, ulcerative colitis, ulcers, etcetera.\n* experiencing regular diarrhea\n* active infection or illness\n* diabetic\n* hypertensive\n* cardiovascular disease\n* breast, uterine, or ovarian cancer\n* uterine fibroids or endometriosis\n* taking medications or supplements that may alter gut health including but not limited to diuretics, laxatives, anti-diarrheal, anticholinergic agents, or antispasmodic agents.\n* previous adverse experience with laxatives\n* taking medications known to interact with the dietary supplement's ingredients including blood pressure medications, anticoagulants, antiplatelets, blood thinners, cholesterol-lowering medications, diuretics, water pills, estrogen based contraceptives, non-steroidal anti-inflammatory drugs, digoxin, corticosteroids, Monoamine oxidase inhibitors, insulin, medications processed in the liver, diclofenac, fluvastatin, glipizide, ibuprofen, piroxicam, phenytoin, phenobarbital, or secobarbital.\n* tobacco user\n* strenuous activity within 24 hours of testing visits\n* caffeine within 24 hours of testing visit\n* alcohol within 24 hours of testing visit",{"count":107,"type":21},30,[24],"The purpose of the present study is to investigate the impact of a natural dietary supplement, Inno Cleanse™, to reduce bloating in a population of otherwise healthy men and women, who claim to feel frequently bloated. Inno CleanseTM dietary supplement is manufactured in the United States under current Good Manufacturing Practices (cGMP) and is marketed by InnoSupps as a digestive health aid. It is sold in the United States on the company's website, Amazon, and in many large retail outlets. It remains a very popular product, with close to 1.4 million units sold since 2020, with a reported 66,000 units sold in the past three months.\n\nDespite the prevalence of dietary supplements identifying as digestive aids, detoxification, and cleanses, very little research has been done to determine their effectiveness. The product appears to be well-designed, with multiple ingredients included which have scientific evidence of effectiveness. That said, and despite the overall positive reviews, there is no known clinical research to support the product's effectiveness.\n\nTherefore, the aim of this study is to evaluate the efficacy of the Inno Cleanse product to reduce bloating and result in other positive outcomes (weight loss). This study will be run as a double-blind placebo-controlled trial, in which subjects will use the product or placebo for two weeks. It is hypothesized that treatment with the dietary supplement Inno Cleanse will result in reduced bloating, as evidenced by self-reported reductions in bloating and hunger, as well as moderate weight loss and a reduction in body circumference measures due to the reduced bloating. In addition, multiple anecdotal reports of improved skin health have been noted in those using the product. Additionally, routine blood and urine sample analysis will be performed as a secondary outcome, as a safety measure.",[87,27],[112],"Inno Cleanse","2026-04-01",{"date":115,"type":32},"2026-04-02",{"date":117,"type":32},"2025-10-07",{"date":119,"type":21},"2026-05-01",{"name":121,"class":39},"University of Memphis",{"id":123,"slug":124,"hasResults":11,"nctId":125,"briefTitle":126,"officialTitle":127,"acronym":4,"eligibilityCriteria":128,"healthyVolunteers":11,"sex":129,"minAge":18,"maxAge":130,"enrollmentInfo":131,"targetDuration":4,"studyType":22,"phases":133,"briefSummary":134,"conditions":135,"keywords":138,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":143,"startDateStruct":145,"completionDateStruct":147,"leadSponsor":149,"locationsCount":40},"100621447","a-clinical-trial-to-investigate-the-safety-and-efficacy-of-bloat-on-gas-and-bloating-in-healthy-women-100621447","NCT07370740","A Clinical Trial to Investigate the Safety and Efficacy of Bloat on Gas and Bloating in Healthy Women","A Randomized, Double-blind, Placebo-controlled, Parallel Clinical Trial to Investigate the Safety and Efficacy of Bloat on Gas and Bloating in Healthy Women","Inclusion Criteria:\n\n1. Females aged 18-65 years, inclusive\n2. Females not of child-bearing potential, defined as those who have undergone a sterilization procedure (e.g. hysterectomy, bilateral oophorectomy, bilateral tubal ligation, complete endometrial ablation) or have been post-menopausal for at least one year prior to screening Or,\n\n   Individuals of child-bearing potential must have a negative baseline urine pregnancy test and agree to use a medically approved method of birth control for the duration of the study. All hormonal birth control must have been in use for a minimum of 3 months. Acceptable methods of birth control include:\n   * Hormonal contraceptives including oral contraceptives, hormone birth control patch (Ortho Evra), vaginal contraceptive ring (NuvaRing), injectable contraceptives (Depo-Provera, Lunelle), or hormone implant (Norplant System)\n   * Double-barrier method\n   * Intrauterine devices\n   * Non-heterosexual lifestyle and agrees to use contraception if planning on changing to heterosexual partner(s)\n   * Vasectomy of partner at least 6 months prior to screening\n   * Abstinence and agrees to use contraception if planning on becoming sexually active during the study\n3. Recurrent bloating and\u002For distension occurring on average at least one day per week which predominates over other GI symptoms as assessed by the QI\n4. Experiences significant gas and bloating after consumption of the standardized meal provided at screening\u002Fbaseline, as assessed by a score of 0 (absent) or 1 (mild) pre-meal and a score of 2 (moderate) or 3 (severe) post-meal\n5. Agrees to maintain current lifestyle habits (diet, physical activity, medications, supplements, and sleep) as much as possible throughout the study\n6. Provided voluntary, written, informed consent to participate in the study\n7. Healthy as determined by medical history as assessed by Qualified Investigator\n\nExclusion Criteria:\n\n1. Individuals who are pregnant, breast feeding, or planning to become pregnant during the study\n2. Participants residing in the same household as another study participant unless they are enrolled consecutively (e.g. not actively enrolled at the same time)\n3. Allergy, sensitivity, intolerance, or dietary restriction preventing consumption of IP, placebo, or standardized meal ingredients\n4. Current or history of any significant diseases of the GI tract or digestive disorders (e.g., irritable bowel syndrome, celiac disease, inflammatory bowel disease, functional constipation, gastroesophageal reflux disease, being treated within the past year for H. pylori infection or gastric ulcer) as assessed by the QI\n5. Unstable metabolic disease or chronic diseases as assessed by the QI\n6. Unstable hypertension. Treatment on a stable dose of medication for at least 3 months will be considered by the QI\n7. Type I or Type II diabetes\n8. Significant cardiovascular event in the past 6 months. Participants with no significant cardiovascular event on stable medication may be included after assessment by the QI on a case-by-case basis\n9. History of or current diagnosis with kidney and\u002For liver diseases as assessed by the QI on a case-by-case basis, with the exception of history of kidney stones in participants who are symptom free for 6 months\n10. Self-reported confirmation of current or pre-existing thyroid condition. Treatment on a stable dose of medication for at least 3 months will be considered by the QI\n11. Major surgery in the past 3 months or individuals who have planned surgery during the course of the study. Participants with minor surgery will be considered on a case-by-case basis by the QI\n12. Cancer, except skin basal cell carcinoma completely excised with no chemotherapy or radiation with a follow up that is negative. Volunteers with cancer in full remission for more than five years after diagnosis are acceptable\n13. Individuals with an autoimmune disease or are immune compromised as assessed by the QI\n14. Chronic use of cannabinoid products (\\>2 times\u002Fweek) as assessed by the QI. Occasional users will be required to washout and abstain for the duration of the study period\n15. Regular use of tobacco or nicotine products in the past 6 months, as assessed by the QI. Occasional users will be required to washout and abstain for the duration of the study period\n16. Alcohol intake average of \\>2 standard drinks per day as assessed by the QI\n17. Alcohol or drug abuse within the last 12 months\n18. Current use of prescribed and\u002For over-the-counter (OTC) medications, supplements, and\u002For consumption of food\u002Fdrinks that may impact the efficacy and\u002For safety of the IP (Section 7.3)\n19. Participation in other clinical research studies 30 days prior to baseline, as assessed by the QI\n20. Individuals who are unable to give informed consent\n21. Any other condition or lifestyle factor, that, in the opinion of the QI, may adversely affect the participant's ability to complete the study or its measures or pose significant risk to the participant","FEMALE","65 Years",{"count":132,"type":21},100,[24],"The goal of this clinical trial is to investigate the safety and efficacy of Bloat on gas and bloating in healthy women. The main question it aims to answer is what is the change in postprandial gas and bloating from pre-dose at t = 60 mins post-dose between Bloat and placebo, as assessed by Gas and Bloating Likert scale at screening\u002Fbaseline.\n\nParticipants will be asked to consume one dose of Bloat or Placebo and answer questionnaires on gas and bloating.",[27,136,137],"Gastrointestinal Symptoms","Intestinal Gas",[139,140,27,137,141],"Bloat","Arrae","Gastrointestinal symptoms","2026-01-21",{"date":144,"type":32},"2026-01-27",{"date":146,"type":21},"2026-05",{"date":148,"type":21},"2026-07",{"name":140,"class":69},{"id":151,"slug":152,"hasResults":11,"nctId":153,"briefTitle":154,"officialTitle":154,"acronym":4,"eligibilityCriteria":155,"healthyVolunteers":16,"sex":17,"minAge":156,"maxAge":157,"enrollmentInfo":158,"targetDuration":4,"studyType":160,"phases":4,"briefSummary":161,"conditions":162,"keywords":168,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":173,"lastUpdatePostDateStruct":174,"startDateStruct":176,"completionDateStruct":178,"leadSponsor":180,"locationsCount":4},"100618878","co-development-and-validation-of-colonic-symptom-pictograms-for-young-people-100618878","NCT07337343","Co-Development and Validation of Colonic Symptom Pictograms for Young People","Inclusion Criteria:\n\nChildren and Young people are aged between 8-17 years,\n\n* have lower gut or constipation symptoms,\n* can communicate in English or be supported to participate by a caregiver, whānau, or other responsible person. Phase Four will include international invitations to participants with lower gut or constipation symptoms. Healthy volunteers will not be recruited.\n\nExclusion Criteria:\n\n* Children and Young people with developmental or cognitive disorder that precludes their ability to understand the study,\n* Children and Young people who do not have access to a digital device with internet connectivity,\n* unable to read English,\n* parent does not consent","8 Years","17 Years",{"count":159,"type":21},120,"OBSERVATIONAL","Severe constipation affects 10% of children, often leading to significant physical and emotional distress. While constipation is commonly associated with impaired bowel movements, it is fundamentally linked to abnormalities in colonic motility - the coordinated contractions that facilitate passage of stool through the colon and out of the body. Diagnosis of constipation is based upon the Rome IV criteria, which assess symptoms as reported or remembered over the previous 3 months.\n\nHowever, reporting symptoms experienced can be challenging for children and young people for many reasons, such as the overlap of sensations, including fullness, bloating, and discomfort, and an inability to recall or precisely distinguish and describe what they are feeling.\n\nThis study intends to design, develop, and validate symptom pictograms for children aged 8-17 with colonic or lower gut symptoms.",[163,164,165,27,166,167],"Constipation - Functional","Abdominal Pain (AP)","Nausea and Vomitting","Flatulence","IBS, Constipation Predominant",[169,170,171,172],"children and adolescents","pictograms","co-design","validation","2026-01-02",{"date":175,"type":32},"2026-01-13",{"date":177,"type":21},"2026-01-01",{"date":179,"type":21},"2027-04-01",{"name":181,"class":39},"University of Auckland, New Zealand",{"id":183,"slug":184,"hasResults":11,"nctId":185,"briefTitle":186,"officialTitle":186,"acronym":4,"eligibilityCriteria":187,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":188,"targetDuration":4,"studyType":22,"phases":190,"briefSummary":192,"conditions":193,"keywords":194,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":196,"lastUpdatePostDateStruct":197,"startDateStruct":199,"completionDateStruct":201,"leadSponsor":203,"locationsCount":40},"100579721","phase-2-a-study-of-microbiome-transplantation-for-the-treatment-of-constipation-andor-significant-bloating-in-patients-with-systemic-sclerosis-100579721","NCT06827977","A Study of Microbiome Transplantation for the Treatment of Constipation and\u002For Significant Bloating in Patients With Systemic Sclerosis","Inclusion Criteria:\n\n* Are seen in the UT Houston Scleroderma Center (UTHSC)\n* Meet 2013 American college of rheumatology (ACR)\u002FEuropean league against rheumatism (EULAR) criteria or CREST criteria for SSc\n* Meet Rome IV criteria for constipation and\u002For significant bloating\n* Subject willing to sign an informed consent form\n* Subject deemed likely to survive for ≥ 1 year after enrollment\n* Able to follow study procedure and follow-up\n* Sexually active male and female subjects of childbearing potential must agree to use an effective method of birth control during the treatment and follow-up period\n* Female subjects of childbearing potential must have a negative pregnancy test in the 72 hours before the procedure\n* Subjects who agree to adhere to a stable diet for at least 4 weeks before joining the study and throughout the study\n* Subjects must have an attending physician who will provide non-transplant care for the subject\n\nExclusion Criteria:\n\n* Subjects with constipation and\u002For significant bloating from causes not attributed to SSc as determined by the treating physician (e.g., inflammatory bowel disease, medication, significant diabetes, or hypothyroidism, etc.)\n* Subjects unwilling to stop taking probiotic supplements during the duration of the study\n* Subjects that have post-total or hemicolectomy or the presence of a colostomy\n* Subjects unable to tolerate microbiome transplant via enema for any reason or swallow capsules\n* Subjects requiring systemic antibiotic therapy 4 weeks before the study\n* If subjects are on immunosuppression, the immunosuppression dose should be stable for at least 4 weeks before study enrollment",{"count":189,"type":21},21,[191],"PHASE2","The purpose of this study is to characterize the intestinal flora in subjects with systemic sclerosis-related constipation and\u002For significant bloating and to determine safety and trends in improvements in the diversity of colonic microbiome and patient symptoms following the administration of either frozen or lyophilized PRIM-DJ2727 microbiota.",[87,27],[195],"Systemic Sclerosis","2025-06-21",{"date":198,"type":32},"2025-06-26",{"date":200,"type":32},"2025-03-03",{"date":202,"type":21},"2026-09-26",{"name":204,"class":39},"The University of Texas Health Science Center, Houston",{"id":206,"slug":207,"hasResults":11,"nctId":208,"briefTitle":209,"officialTitle":209,"acronym":4,"eligibilityCriteria":210,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":211,"enrollmentInfo":212,"targetDuration":4,"studyType":160,"phases":4,"briefSummary":214,"conditions":215,"keywords":222,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":228,"lastUpdatePostDateStruct":229,"startDateStruct":231,"completionDateStruct":233,"leadSponsor":235,"locationsCount":40},"100574160","a-prospective-multicentre-real-world-assessment-of-the-efficacy-of-danning-tablets-in-alleviating-digestive-symptoms-100574160","NCT06755671","A Prospective Multicentre Real-world Assessment of the Efficacy of Danning Tablets in Alleviating Digestive Symptoms","Inclusion Criteria:\n\n* Patients between 18 and 75 years old\n* Patients with at least one of the following symptoms: upper abdominal pain, bloating, loss of appetite, acid reflux or constipation\n* Patients already taking Danning Tablets as part of their regular medicine treatment for dyspepsia\n* Patients agree to sign the informed consent form\n\nExclusion Criteria:\n\n* Past history or comorbidity of malignant tumor\n* Comorbidity of severe systemic condition including cardiovascular, cerebrovascular, renal and hematopoietic system diseases\n* Past history of abdominal surgery (post pancreatic surgery, post subtotal gastrectomy; incomplete intestinal obstruction) or mental illness, mobility difficulty (e.g. long-term bed ridden)\n* Comorbidity of any unstable chronic or acute disease,which may impact the evaluation of treatment efficacy as determined by the research physician\n* Pregnancy or breastfeeding\n* Participation in other clinical trials within the past 3 months\n* Other circumstances determined as ineligible by the research physician","75 Years",{"count":213,"type":21},4500,"The goal of this observational study is to evaluate if Danning Tablets are effective in alleviating dyspepsia in patients with any of the following digestive symptoms: upper abdominal pain, bloating, loss of appetite, acid reflux or constipation.\n\nThe main questions it aims to answer are:\n\nHow effective are Danning Tablets for patients with indigestion symptoms? What are the impact factors (e.g. severity of conditions, demographic features, dose and length of treatment etc.) of the efficacy of Danning Tablets for indigestion patients?\n\nParticipants already taking Danning Tablets as part of their regular medical care for indigestion will take questionnaires by the end of two weeks and four weeks respectively from the start of their treatment.",[216,217,27,218,219,87,220,221],"Indigestion","Dyspepsia","Loss of Appetite","Reflux Acid","Upper Abdominal Pain","Functional Dyspepsia",[223,224,225,226,227],"Danning Tablets","dyspepsia","indigestion","observational study","real world study","2025-05-13",{"date":230,"type":32},"2025-05-14",{"date":232,"type":32},"2025-04-30",{"date":234,"type":21},"2027-06-30",{"name":236,"class":69},"Shanghai Hutchison Pharmaceuticals Limited",{"id":238,"slug":239,"hasResults":11,"nctId":240,"briefTitle":241,"officialTitle":242,"acronym":4,"eligibilityCriteria":243,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":244,"targetDuration":4,"studyType":22,"phases":246,"briefSummary":247,"conditions":248,"keywords":250,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":254,"lastUpdatePostDateStruct":255,"startDateStruct":257,"completionDateStruct":259,"leadSponsor":261,"locationsCount":4},"100583086","effect-of-a-low-fodmap-diet-in-ibs-and-functional-constipation-with-bloating-a-randomized-double-blind-trial-100583086","NCT06871748","Effect of a Low FODMAP Diet in IBS and Functional Constipation with Bloating: a Randomized Double-Blind Trial","Effect of a Low FODMAP Diet in Irritable Bowel Syndrome and Functional Constipation with Bloating: a Randomized Double-Blind Controlled Trial with Microbiota, Intestinal Gas, and Metabolomic Analysis","Inclusion Criteria:\n\n* Age ≥18 years\n* Diagnosed with Irritable Bowel Syndrome (IBS) or Functional Constipation (FC) based on Rome IV criteria\n* Persistent bloating affecting daily life, with a bloating VAS score ≥4\n* Stable bowel habits with Bristol Stool Form Scale (BSFS) type 3-5\n* History of prior treatment with antispasmodics and\u002For prokinetics (allowed if dose remains stable)\n* Able to comply with dietary intervention and study procedures\n\nExclusion Criteria:\n\n* Prior gastrointestinal surgery (except appendectomy or cholecystectomy)\n* Use of antibiotics, proton pump inhibitors (PPIs), probiotics, NSAIDs, lactulose, or metformin within the past 4 weeks\n* Presence of systemic diseases affecting gut microbiota (e.g., liver cirrhosis, uncontrolled diabetes, end-stage renal disease, obesity, cancer, psychiatric disorders)\n* Inability to consume study meals or follow dietary restrictions",{"count":245,"type":21},34,[24],"This clinical study aims to evaluate the effects of a low FODMAP diet compared to a high FODMAP diet in patients with Irritable Bowel Syndrome (IBS) and Functional Constipation (FC) with predominant bloating. The study is a randomized, double-blind, controlled trial designed to assess whether a diet low in fermentable carbohydrates can improve bloating symptoms, gut microbiota composition, intestinal gas production, and metabolic outputs.\n\nPatients meeting the Rome IV criteria for IBS or FC with persistent bloating will be enrolled and randomly assigned to receive either a low or high FODMAP diet for two weeks. Meals will be standardized to control FODMAPs composition, ensuring that FODMAP content is the primary variable.\n\nThe primary endpoint is the proportion of participants with a ≥30% reduction in bloating severity, measured using the Visual Analog Scale (VAS). Secondary outcomes include changes in global IBS symptoms, abdominal pain, bowel movements, stool consistency, microbiota diversity, hydrogen\u002Fmethane gas production, and metabolomic profiles.\n\nThis study will contribute to the growing body of evidence supporting dietary management in disorders of gut-brain interaction (DGBI), particularly in bloating-predominant IBS and FC, and will provide insights into the mechanisms linking diet, gut microbiota, and symptom improvement.",[249,163,27],"Irritable Bowel Syndrome (IBS)",[249,251,252,253],"Functional Constipation","FODMAP","Microbiota","2025-03-06",{"date":256,"type":32},"2025-03-12",{"date":258,"type":21},"2025-03-15",{"date":260,"type":21},"2026-07-31",{"name":99,"class":39},{"id":263,"slug":264,"hasResults":11,"nctId":265,"briefTitle":266,"officialTitle":267,"acronym":4,"eligibilityCriteria":268,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":269,"enrollmentInfo":270,"targetDuration":4,"studyType":22,"phases":271,"briefSummary":272,"conditions":273,"keywords":276,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":282,"lastUpdatePostDateStruct":283,"startDateStruct":285,"completionDateStruct":287,"leadSponsor":289,"locationsCount":40},"100565483","fiber-product-for-gas-bloating-and-bowel-regularity-100565483","NCT06642766","Fiber Product for Gas, Bloating, and Bowel Regularity","Open Label Study of a Novel, Commercially Available Fiber Product for Gas, Bloating, and Bowel Regularity","Inclusion Criteria:\n\n* Subjects have experienced two or more of the following criteria for at least 3 months with symptom onset at least 6 months prior: straining during at least 25% of defecations, lumpy or hard stools in at least 25% of defecations, sensation of incomplete evacuation for at least 25% of defecations, sensation of anorectal obstruction\u002Fblockage for at least 25% of defecations, manual maneuvers to facilitate at least 25% of defecations (e.g., digital evacuation, support of the pelvic floor), loose stools are rarely present without the use of laxatives Or,\n* Subjects have experienced 2 or more of the following criteria of recurrent abdominal pain, for at least 3 months, with symptom onset at least 6 months prior: pain related to defecation, associated with a change in frequency of stool, associated with a change in form (appearance) of stool Or,\n* Subjects have experienced 2 or more of the following criteria for at least 3 months, with symptom onset at least 6 months prior: recurrent abdominal pain, on average, at least 1 day per week in the last 3 months associated with two of the following criteria: pain related to defecation, pain associated with a change in frequency of stool and pain associated with a change in form (appearance) of stool.\n* The subject predominantly experiences loose or watery stools (Bristol Stool Form Scale types 6-7), more than 25% of the time, or hard or lumpy stools (types 1-2) less than 25% of the time.\n* The symptoms should be chronic and interfere with daily activities, cause worry or affect the quality of life.\n\nExclusion Criteria:\n\n* Loose stools are present for more than 25% of defecations\n* Unable to provide informed consent\n* Hematochezia\n* Prior colon surgery\n* Thyroid disease\n* Pelvic floor disorder\n* Known allergies or intolerance to fiber products\n* infectious diarrhea or food poisoning\n* inflammatory bowel disease, including microscopic colitis\n* fecal incontinence or rectal prolapse","90 Years",{"count":132,"type":21},[24],"This is a new, commercially available, over-the-counter fiber supplement that combines 8 fibers. The varied nature of the fibers in this product is designed to create a more diverse microbiome (bacteria that live within the human GI tract). In general, the more diverse the microbiome the less inflammatory the gut. The purpose of this study is to evaluate the effects of a new fiber product on bloating, gas, and bowel movements.",[27,274,275],"Bowel Irregularities","Bowel Gas",[277,56,278,279,280,281],"fiber supplement","nutralieve","Microbiome","Gut microbiota","irregular bowel movements","2024-10-11",{"date":284,"type":32},"2024-10-15",{"date":286,"type":21},"2024-10",{"date":288,"type":21},"2025-05",{"name":290,"class":69},"Bell Cinical Service"]